TY - JOUR
T1 - Impact of HLA disparity on the risk of overall mortality in patients with grade II–IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation
AU - Fuji, Shigeo
AU - Hakoda, Akitoshi
AU - Kanda, Junya
AU - Murata, Makoto
AU - Terakura, Seitaro
AU - Inamoto, Yoshihiro
AU - Uchida, Naoyuki
AU - Toya, Takashi
AU - Eto, Tetsuya
AU - Nakamae, Hirohisa
AU - Ikegame, Kazuhiro
AU - Tanaka, Masatsugu
AU - Kawakita, Toshiro
AU - Kondo, Tadakazu
AU - Miyamoto, Toshihiro
AU - Fukuda, Takahiro
AU - Ichinohe, Tatsuo
AU - Kimura, Takafumi
AU - Atsuta, Yoshiko
AU - Shintani, Ayumi
AU - Morishima, Satoko
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/12
Y1 - 2021/12
N2 - Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Stem cell source or HLA disparity may exert a significant impact on the overall survival (OS) after the development of aGVHD. In order to clarify this point, we performed a retrospective analysis using a database of the Japan Society for HCT. We analyzed the clinical outcomes of 10,035 patients who developed grade II–IV aGVHD. The median age of the patients was 48 years. The probability of 2-year OS after the onset of grade II–IV aGVHD in the study cohort was 54.1%. The multivariate analysis showed that the HLA ≥2-loci mismatched related donor and HLA 1-locus mismatched unrelated donor were significantly associated with an inferior OS after grade II–IV aGVHD. In a subgroup analysis, peripheral blood stem cells and HLA disparity were associated with an inferior OS in patients who received related or unrelated HCT. Thus, the clinical outcome after grade II–IV aGVHD significantly varied as per the combination of the presence of HLA disparity and stem cell source. Further research using other databases is necessary to confirm our findings.
AB - Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Stem cell source or HLA disparity may exert a significant impact on the overall survival (OS) after the development of aGVHD. In order to clarify this point, we performed a retrospective analysis using a database of the Japan Society for HCT. We analyzed the clinical outcomes of 10,035 patients who developed grade II–IV aGVHD. The median age of the patients was 48 years. The probability of 2-year OS after the onset of grade II–IV aGVHD in the study cohort was 54.1%. The multivariate analysis showed that the HLA ≥2-loci mismatched related donor and HLA 1-locus mismatched unrelated donor were significantly associated with an inferior OS after grade II–IV aGVHD. In a subgroup analysis, peripheral blood stem cells and HLA disparity were associated with an inferior OS in patients who received related or unrelated HCT. Thus, the clinical outcome after grade II–IV aGVHD significantly varied as per the combination of the presence of HLA disparity and stem cell source. Further research using other databases is necessary to confirm our findings.
UR - http://www.scopus.com/inward/record.url?scp=85114618759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114618759&partnerID=8YFLogxK
U2 - 10.1038/s41409-021-01443-2
DO - 10.1038/s41409-021-01443-2
M3 - Article
C2 - 34480119
AN - SCOPUS:85114618759
SN - 0268-3369
VL - 56
SP - 2990
EP - 2996
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 12
ER -